These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 8581384)

  • 1. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
    Weiner LM; Clark JI; Ring DB; Alpaugh RK
    J Hematother; 1995 Oct; 4(5):453-6. PubMed ID: 8581384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
    Weiner LM; Clark JI; Davey M; Li WS; Garcia de Palazzo I; Ring DB; Alpaugh RK
    Cancer Res; 1995 Oct; 55(20):4586-93. PubMed ID: 7553634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
    Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
    Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment.
    Clark JI; Alpaugh RK; von Mehren M; Schultz J; Gralow JR; Cheever MA; Ring DB; Weiner LM
    Cancer Immunol Immunother; 1997 Jul; 44(5):265-72. PubMed ID: 9247561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human Fc gamma RIII.
    Weiner LM; Alpaugh RK; Amoroso AR; Adams GP; Ring DB; Barth MW
    Cancer Immunol Immunother; 1996 Mar; 42(3):141-50. PubMed ID: 8640842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
    Repp R; Valerius T; Wieland G; Becker W; Steininger H; Deo Y; Helm G; Gramatzki M; Van de Winkel JG; Lang N
    J Hematother; 1995 Oct; 4(5):415-21. PubMed ID: 8581378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1.
    Weiner LM; Holmes M; Richeson A; Godwin A; Adams GP; Hsieh-Ma ST; Ring DB; Alpaugh RK
    J Immunol; 1993 Sep; 151(5):2877-86. PubMed ID: 8103070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro cytotoxic targeting by human mononuclear cells and bispecific antibody 2B1, recognizing c-erbB-2 protooncogene product and Fc gamma receptor III.
    Hsieh-Ma ST; Eaton AM; Shi T; Ring DB
    Cancer Res; 1992 Dec; 52(24):6832-9. PubMed ID: 1360872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group.
    Borghaei H; Alpaugh RK; Bernardo P; Palazzo IE; Dutcher JP; Venkatraj U; Wood WC; Goldstein L; Weiner LM
    J Immunother; 2007; 30(4):455-67. PubMed ID: 17457220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format.
    Shahied LS; Tang Y; Alpaugh RK; Somer R; Greenspon D; Weiner LM
    J Biol Chem; 2004 Dec; 279(52):53907-14. PubMed ID: 15471859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
    Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
    Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
    Stockmeyer B; Valerius T; Repp R; Heijnen IA; Bühring HJ; Deo YM; Kalden JR; Gramatzki M; van de Winkel JG
    Cancer Res; 1997 Feb; 57(4):696-701. PubMed ID: 9044847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu.
    Valone FH; Kaufman PA; Guyre PM; Lewis LD; Memoli V; Ernstoff MS; Wells W; Barth R; Deo Y; Fisher J
    J Hematother; 1995 Oct; 4(5):471-5. PubMed ID: 8581387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16.
    Garcia de Palazzo I; Holmes M; Gercel-Taylor C; Weiner LM
    Cancer Res; 1992 Oct; 52(20):5713-9. PubMed ID: 1394194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies.
    Renner C; Pfreundschuh M
    J Hematother; 1995 Oct; 4(5):447-51. PubMed ID: 8581383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical detection of c-erbB-2 expression by neoplastic human tissue using monospecific and bispecific monoclonal antibodies.
    Garcia de Palazzo I; Klein-Szanto A; Weiner LM
    Int J Biol Markers; 1993; 8(4):233-9. PubMed ID: 7908024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.
    McCall AM; Adams GP; Amoroso AR; Nielsen UB; Zhang L; Horak E; Simmons H; Schier R; Marks JD; Weiner LM
    Mol Immunol; 1999 May; 36(7):433-45. PubMed ID: 10449096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).
    Ball ED; Guyre PM; Mills L; Fisher J; Dinces NB; Fanger MW
    J Hematother; 1992; 1(1):85-94. PubMed ID: 1365020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells.
    Somasundaram C; Sundarapandiyan K; Keler T; Deo YM; Graziano RF
    Hum Antibodies; 1999; 9(1):47-54. PubMed ID: 10331185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo.
    Wallace PK; Kaufman PA; Lewis LD; Keler T; Givan AL; Fisher JL; Waugh MG; Wahner AE; Guyre PM; Fanger MW; Ernstoff MS
    J Immunol Methods; 2001 Feb; 248(1-2):167-82. PubMed ID: 11223077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.